Medite Cancer Diagnostics, Inc.
MDIT
$0.00
$0.000.00%
| 09/30/2018 | 06/30/2018 | 03/31/2018 | 12/31/2017 | 09/30/2017 | |
|---|---|---|---|---|---|
| Revenue | -- | 7.43M | 6.43M | 6.81M | 6.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 7.43M | 6.43M | 6.81M | 6.81M |
| Cost of Revenue | -- | 6.60M | 6.61M | 6.65M | 5.27M |
| Gross Profit | -- | 828.00K | -183.00K | 162.00K | 1.54M |
| SG&A Expenses | -- | 4.95M | 5.42M | 5.28M | 4.22M |
| Depreciation & Amortization | -- | 329.00K | 315.00K | 293.00K | 273.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 12.87M | 13.41M | 13.41M | 11.33M |
| Operating Income | -- | -5.45M | -6.98M | -6.60M | -4.53M |
| Income Before Tax | -- | -6.68M | -7.75M | -7.30M | -5.33M |
| Income Tax Expenses | -- | -487.00K | -487.00K | -487.00K | -115.00K |
| Earnings from Continuing Operations | -- | -6.20 | -7.26 | -6.81 | -5.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -6.20M | -7.26M | -6.81M | -5.22M |
| EBIT | -- | -5.45M | -6.98M | -6.60M | -4.53M |
| EBITDA | -- | -5.12M | -6.67M | -6.31M | -4.25M |
| EPS Basic | -- | -0.20 | -0.25 | -0.25 | -0.21 |
| Normalized Basic EPS | -- | -0.13 | -0.17 | -0.17 | -0.13 |
| EPS Diluted | -- | -0.20 | -0.25 | -0.25 | -0.21 |
| Normalized Diluted EPS | -- | -0.13 | -0.17 | -0.17 | -0.13 |
| Average Basic Shares Outstanding | -- | 151.91M | 122.31M | 106.08M | 98.81M |
| Average Diluted Shares Outstanding | -- | 151.91M | 122.31M | 106.08M | 98.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
